Courtenay Special Situations Fund Falls 14% in July, Adds to Elon Musk-Linked Stakes
GA-Courtenay Special Situations Fund declined 13.8% in July, taking its year-to-date return to -10.0%, as an unusual liquidity-driven dislocation...
95 Views
Samsung Biologics (207940 KS): 2025 Revenue Meet Guidance; Big Fat Order Book Lends Visibility Ahead
Samsung Biologics reported 2025 revenue growth of 30% YoY, driven by successful ramp-up of Plant 4. 2025 annual order intake surpassed KRW6T mark,...
414 Views
Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance
Samsung Biologics secures first U.S. manufacturing site through acquiring a GSK biologics facility, having 60K liters of drug substance capacity...
682 Views
Samsung Bioepis Holdings and Samsung Biologics to Start Trading on 24 November
Samsung Biologics and Samsung Bioepis Holdings will start trading on 24 November with positive outlook due to improving operating leverage and...
622 Views
Samsung Biologics (207940 KS/Buy)Spin-Off Likely to Unlock Additional Value
We raise our target price for Samsung Biologics to W1,600,000 (from W1,400,000), which is based on the sum of the values of the CDMO business...
591 Views